What Is the Best Medication or Treatment Plan for PCOS?

How Common Is PCOS and Why Does Treatment Vary So Much?

PCOS affects 8 to 13% of reproductive-age women globally, making it the most common endocrine disorder in this population according to the World Health Organization [1]. Diagnosis follows the Rotterdam criteria: two of three features must be present, namely oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound [2].

Treatment varies because PCOS is not one disease. It is a syndrome with at least four phenotypes. Phenotype A (all three Rotterdam features) carries the heaviest metabolic burden. Phenotype D (anovulation plus polycystic morphology, no androgen excess) carries far less cardiovascular risk. A medication that is first-line for one phenotype may be irrelevant or even counterproductive for another.

The Three Therapeutic Targets

Every effective treatment plan addresses at least one of these three mechanisms:

1. Androgen excess. Elevated testosterone and DHEAS drive hirsutism, acne, and scalp hair loss.
2. Insulin resistance. Present in 65 to 80% of women with PCOS regardless of body weight, insulin resistance amplifies ovarian androgen production [3].
3. Anovulation. Irregular or absent ovulation is the proximate cause of menstrual irregularity and subfertility.

Who Decides the Plan?

The treating clinician's first question should be: "Is pregnancy the goal in the next 6 to 12 months?" The answer restructures the entire treatment algorithm. Combined oral contraceptives, which are first-line for menstrual regulation, are obviously contraindicated during a fertility cycle. Spironolactone requires reliable contraception because of teratogenicity risk. Letrozole is used only when ovulation induction is the goal.

The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS (developed jointly by Monash University, the European Society of Human Reproduction and Embryology, and the American Society for Reproductive Medicine) provides the framework most clinicians use today [4].

Lifestyle Modification: The Foundation of Every Plan

Lifestyle intervention is not a soft option. A 5 to 10% reduction in body weight in women with overweight or obesity can restore spontaneous ovulation, reduce androgen levels, and improve insulin sensitivity without a single prescription [5].

The 2023 international guideline states directly: "Healthy lifestyle behaviours, including regular physical activity and a healthy diet, are recommended for all women with PCOS to optimize general health." [4] The guideline does not endorse one specific diet pattern over another, though low-glycemic-index diets and Mediterranean-style eating both show measurable benefit in randomized controlled trials.

Exercise Specifics

A Cochrane review of lifestyle interventions in PCOS (2019, 27 trials, N=1,279) found that exercise reduced fasting insulin, improved menstrual frequency, and reduced free androgen index compared to minimal intervention [6]. Both aerobic and resistance training produced benefit. At least 150 minutes per week of moderate-intensity aerobic activity is the standard recommendation, consistent with the American Heart Association's general guidance [7].

Diet and Caloric Targets

Caloric deficit remains the driver of weight loss in PCOS, with macronutrient composition playing a secondary role. A 12-week randomized trial comparing low-carbohydrate versus low-fat diets in 96 women with PCOS found comparable weight loss but greater reductions in testosterone with the low-carbohydrate approach [8]. A clinician may reasonably recommend a low-glycemic-index diet as a starting point while noting that adherence is more predictive of outcomes than any specific macronutrient ratio.

Combined Oral Contraceptives: First-Line for Menstrual and Androgen Symptoms

For women with PCOS who are not currently trying to conceive, the combined oral contraceptive pill (COCP) is the first-line pharmacological option for regulating menstrual cycles and reducing androgen-driven symptoms such as acne and hirsutism [4].

COCPs work through two mechanisms. First, the progestin component suppresses LH, which in turn reduces ovarian androgen production. Second, the estrogen component increases sex hormone-binding globulin (SHBG), which binds free testosterone and reduces its bioavailability.

Which Pill Formulation?

The evidence base does not clearly favor one COCP formulation over another for PCOS specifically. Pills containing anti-androgenic progestins, such as drospirenone (e.g., Yasmin, Yaz) or cyproterone acetate (not available in the United States), are often selected when hirsutism or acne is prominent. A 2017 Cochrane review of 10 trials (N=1,787) found no clinically meaningful superiority of any one COCP formulation for hirsutism outcomes [9].

Metabolic Considerations

Some COCPs mildly worsen insulin resistance and triglyceride levels. Women with PCOS who have pre-existing dyslipidemia or impaired fasting glucose should have metabolic labs reassessed 3 to 6 months after starting a COCP. If insulin resistance worsens, adding metformin is reasonable [4].

Duration and Monitoring

A minimum trial of 6 months is needed to assess hirsutism response, because hair follicle cycles are slow. Acne may improve within 3 months. If menstrual regulation is the only goal and metabolic risk is low, the COCP can be continued long-term with annual blood pressure monitoring.

Metformin: The Core Insulin-Sensitizer

Metformin is a biguanide that reduces hepatic glucose output and improves peripheral insulin sensitivity. The 2023 international PCOS guideline recommends metformin for women with PCOS who have a BMI above 25 kg/m², for adolescents with metabolic features, and as an adjunct to ovulation induction [4].

The standard target dose is 1,500 to 2,550 mg/day in divided doses with meals to minimize gastrointestinal side effects. Extended-release formulations (metformin XR) have equivalent efficacy with better GI tolerability for most patients.

Metformin and Menstrual Regularity

A meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (44 RCTs, N=3,789) found that metformin significantly improved menstrual frequency versus placebo, with an odds ratio of 2.76 (95% CI 2.05 to 3.72, P<0.001) [10]. This effect is most pronounced in women with insulin resistance.

Metformin for Ovulation Induction

When used alone for ovulation induction, metformin is less effective than letrozole. The landmark PPCOS II trial (N=750) found live birth rates of 27.5% with letrozole versus 19.1% with clomiphene versus 7.2% with metformin alone over six ovulatory cycles [11]. Metformin is most useful as an adjunct to letrozole in clomiphene-resistant cases or in women with marked insulin resistance.

Practical Starting Protocol

Start at 500 mg with dinner for 1 week, then increase to 500 mg twice daily, then to the target dose over 4 to 6 weeks. Check baseline HbA1c and renal function. The drug is contraindicated when eGFR falls below 30 mL/min/1.73m².

Letrozole: Preferred Drug for Ovulation Induction

For women with PCOS who want to conceive and have not responded to lifestyle modification, letrozole is the first-line ovulation induction agent per the 2023 international guideline, which explicitly states it "should be used in preference to clomiphene citrate" [4].

Letrozole is an aromatase inhibitor, not a selective estrogen receptor modulator. It reduces estrogen production transiently, which triggers a strong FSH surge and monofollicular development more reliably than clomiphene, reducing the risk of multiple gestation.

Dosing Protocol

Standard starting dose is 2.5 mg on days 3 to 7 of a natural or progestin-induced menstrual cycle. The dose can be increased to 5 mg and then 7.5 mg in subsequent cycles if ovulation does not occur. Ultrasound follicle monitoring from day 10 allows timed intercourse or intrauterine insemination.

Evidence from the PPCOS II Trial

The landmark PPCOS II trial, a multicenter RCT (N=750) published in the New England Journal of Medicine, found that letrozole produced a live birth rate of 27.5% versus 19.1% for clomiphene citrate (P=0.007) and resulted in lower rates of twin pregnancies [11]. This trial shifted the guideline consensus from clomiphene to letrozole as the default first-line agent.

When to Escalate

After 6 failed letrozole cycles with confirmed ovulation, the next step is typically gonadotropin injections (FSH) or referral for IVF. Women with very high BMI (>35 kg/m²) may have reduced letrozole response and benefit from weight loss or a GLP-1 receptor agonist before another ovulation induction attempt.

Spironolactone: Targeted Anti-Androgen Therapy

Spironolactone is an aldosterone antagonist with potent anti-androgenic properties. At doses of 50 to 200 mg/day, it blocks the androgen receptor and inhibits 5-alpha-reductase, making it effective for hirsutism and acne in women with PCOS for whom the COCP alone is insufficient [4].

A randomized trial published in the Journal of the American Academy of Dermatology (N=40) found that spironolactone 100 mg/day reduced the modified Ferriman-Gallwey hirsutism score by 40% at 6 months compared to 8% with placebo (P<0.001) [12].

Contraception Requirement

Spironolactone is teratogenic and carries a risk of feminizing a male fetus. Any prescribing clinician must confirm that the patient is using reliable contraception. The drug is almost always co-prescribed with a COCP in this context, which also provides the SHBG-raising effect noted above.

Monitoring

Check serum potassium and blood pressure at baseline and at 4 to 6 weeks. Hyperkalemia is uncommon in young healthy women with normal renal function but becomes relevant if NSAIDs or ACE inhibitors are used concurrently. Menstrual irregularity is common at doses above 100 mg; the concurrent COCP prevents this.

GLP-1 Receptor Agonists: An Evidence-Backed Emerging Option

GLP-1 receptor agonists, including liraglutide and semaglutide, are not yet approved by the FDA specifically for PCOS, but clinical trial data support their use in insulin-resistant women with PCOS who have obesity or significant metabolic dysfunction [13].

Weight and Androgen Reduction

A 2022 randomized controlled trial published in Diabetes, Obesity and Metabolism (N=116) compared liraglutide 1.8 mg/day to metformin 1,000 mg twice daily over 12 weeks in women with PCOS. Liraglutide produced significantly greater reductions in body weight (5.2% vs. 2.1%, P<0.01), free testosterone index, and LH/FSH ratio [14].

Semaglutide 2.4 mg weekly (the dose studied in the STEP-1 trial, N=1,961) produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [15]. Weight loss of this magnitude in women with PCOS who have obesity is expected to substantially improve ovarian function, based on the dose-response relationship between adiposity and androgen excess.

Practical Considerations

GLP-1 receptor agonists require off-label prescribing for PCOS unless type 2 diabetes or obesity (BMI >30 kg/m²) is also documented. Insurance coverage is inconsistent. Nausea is the most common side effect and is reduced by slow dose titration. These agents are contraindicated in personal or family history of medullary thyroid carcinoma or MEN2.

A Suggested Decision Point for GLP-1 Use in PCOS

A reasonable clinical threshold for adding a GLP-1 receptor agonist to a PCOS treatment plan includes all of the following: BMI >30 kg/m², documented insulin resistance (fasting insulin above 15 uIU/mL or HOMA-IR above 2.5), and inadequate response to at least 3 months of metformin plus lifestyle modification. This three-criterion gateway aligns with the population enrolled in the liraglutide PCOS trials and with the FDA's approved indications for obesity pharmacotherapy.

Inositol: The Evidence-Supported Supplement

Myo-inositol and D-chiro-inositol are naturally occurring insulin-sensitizing compounds. They are not FDA-approved drugs but have a meaningful randomized trial base that supports their use as adjuncts in PCOS management.

A 2019 meta-analysis in Reproductive BioMedicine Online (16 RCTs, N=1,029) found that myo-inositol supplementation improved menstrual regularity, reduced fasting insulin, and lowered androgen levels versus placebo, with no serious adverse events reported [16]. The most studied dose is myo-inositol 2 to 4 g/day, often combined with D-chiro-inositol in a 40:1 ratio mirroring physiological tissue concentrations.

Position in the Treatment Algorithm

Inositol occupies a useful middle ground for women who have mild insulin resistance, prefer to minimize prescription medications, or have contraindications to metformin. It is not a substitute for metformin in women with impaired fasting glucose or type 2 diabetes risk, but it may be tried before metformin in younger women with mild metabolic features.

The 2023 international PCOS guideline acknowledges inositol's evidence base while noting that longer and larger trials are still needed before a definitive recommendation can be made [4].

Screening and Long-Term Metabolic Monitoring

PCOS is a lifelong condition that persists beyond menopause in many women, with elevated cardiovascular and type 2 diabetes risk carrying through life. A diagnostic workup at the time of PCOS diagnosis should include fasting glucose, HbA1c or 2-hour 75 g OGTT, fasting lipid panel, blood pressure, and waist circumference [4].

The American Diabetes Association recommends that women with PCOS be screened for prediabetes and type 2 diabetes every 1 to 3 years, or sooner if risk factors worsen [17]. The lifetime risk of developing type 2 diabetes in women with PCOS is approximately 4-fold higher than in age-matched controls without the condition [3].

Cardiovascular Risk

Women with PCOS have a 2-fold higher prevalence of hypertension and dyslipidemia compared to women without PCOS matched for age and BMI [18]. Statin therapy follows standard lipid guidelines; there is no PCOS-specific lipid threshold. Aspirin for primary prevention follows the USPSTF 2022 guidance, which does not recommend routine low-dose aspirin for primary cardiovascular prevention in most adults [19].

Mental Health Screening

Rates of depression and anxiety are 3- to 4-fold higher in women with PCOS than in the general population [4]. Every clinical visit should include a brief assessment using a validated tool such as the PHQ-9 or GAD-7. Referral to behavioral health services is part of comprehensive PCOS care, not an optional add-on.

Putting the Plan Together: A Symptom-Based Framework

The table below summarizes how the major treatment options map to the primary presenting concern.

| Primary Goal | First-Line | Second-Line | Notes | |---|---|---|---| | Menstrual regulation (no fertility goal) | COCP | Metformin | Add metformin if insulin resistance present | | Hirsutism / acne | COCP | COCP + spironolactone 100 mg/day | 6-month trial needed | | Ovulation induction | Lifestyle + letrozole 2.5 to 7.5 mg | Letrozole + metformin | Clomiphene if letrozole unavailable | | Weight and metabolic control | Lifestyle + metformin | GLP-1 agonist if BMI >30 | GLP-1 is off-label for PCOS | | Mild insulin resistance, medication-averse | Myo-inositol 2 to 4 g/day | Metformin | Insufficient evidence to replace metformin in high-risk patients |

Women with PCOS frequently have more than one primary concern simultaneously. A 28-year-old woman with obesity, hirsutism, and a desire to conceive in 12 months may be best served by a 6-month intensive lifestyle and metformin phase, followed by letrozole-based ovulation induction, with spironolactone deferred until after any planned pregnancies. The individual plan always requires balancing fertility timing against the slower timelines of androgen symptom treatment.

The American Society for Reproductive Medicine's 2020 practice committee opinion on ovulation induction recommends that all women undergoing ovulation induction for PCOS have a pre-treatment assessment of ovarian reserve, uterine anatomy, and partner semen analysis before initiating pharmacological cycles [20].